Elitek Efficacy, Onset Of Action Are Advantages Over Allopurinol, Sanofi Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sanofi-Synthelabo is highlighting the efficacy and onset of action of its uricolytic agent Elitek (rasburicase) compared to allopurinol, the standard treatment for hyperuricemia.